Candel Therapeutics (CADL) is back in focus after reporting second quarter 2026 results that showed a net loss of US$38.91 million. This compared with net income for the first half of 2025.

The earnings release has come alongside strong momentum in Candel Therapeutics' stock, with a 1 month share price return of 37.34% and a year to date share price return of 141.36%. The 3 year total shareholder return is very large at around 9x, suggesting investors are reassessing both the risk around widening losses and the potential impact of upcoming clinical and regulatory milestones.

If this kind of move has your attention, it can be useful to see what else is gaining traction in related areas and compare with 40 healthcare AI stocks.

Candel Therapeutics now combines a very large multi year share price gain with deep current losses. The products and pipeline are only one side of the story. How does the current share price compare with that reality?

Preferred Price to Book of 8x: Is it justified?

Candel Therapeutics closed at $13.13 and is currently described as trading at a very large discount to one fair value estimate based on the SWS DCF model, yet on a price to book basis the stock is described as expensive relative to both the broader US Biotechs industry and its closest peers.

The preferred multiple in focus here is the P/B ratio. This compares the market value of Candel Therapeutics' equity to its book value, which can be a useful cross check for asset intensive or early stage biopharmaceutical companies that have limited current revenue but significant R&D investment and intellectual property on the balance sheet.

According to the data, Candel Therapeutics trades on a P/B of 8x. That is well above the US Biotechs industry average of 2.5x and the peer group average of 2.2x. At the same time, the company is currently unprofitable, reports no meaningful revenue, has a negative return on equity of 70.19% and has reported increasing losses over the past five years. This combination suggests the market is already pricing in a substantial amount of future progress despite the absence of current earnings support.

When a stock trades on a multiple more than three times the sector and peer averages, as Candel Therapeutics currently does on P/B, it signals that investors are placing a much higher value on its pipeline and prospective cash flows than on its current balance sheet. If sentiment or expectations around those future outcomes change, the P/B multiple is one of the areas that could adjust.

Result: Price to book of 8x (OVERVALUED)

However, Candel Therapeutics depends on unproven clinical programs and continues to report sizeable losses, so any trial setback or funding pressure could quickly affect sentiment.

Another View on Candel Therapeutics' Value

While Candel Therapeutics looks expensive on a P/B of 8x, the SWS DCF model points in the opposite direction. It suggests the stock at $13.13 trades at a very large discount to an estimated future cash flow value of $313.53. That is a huge gap for any investor to weigh.

For a closer look at how this cash flow view is built and what would need to go right for Candel Therapeutics to reach that implied value, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Candel Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

After weighing both the enthusiasm and the clear risks around Candel Therapeutics, it makes sense to review the data directly and not just the headline story. If you want a balanced snapshot of what could go right and what could go wrong, start with these 2 key rewards and 2 important warning signs

Looking for more Candel Therapeutics style investment ideas?

If Candel Therapeutics has you rethinking your watchlist, now is a good time to broaden your search before the next wave of opportunities moves ahead.

• Target potential mispricings by scanning for companies that combine quality with compelling valuations through the 48 high quality undervalued stocks.
• Strengthen your core holdings by focusing on businesses with resilient finances using the solid balance sheet and fundamentals stocks screener (50 results).
• Hunt for under-followed opportunities that could be overlooked by many investors by checking the screener containing 17 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.